Most people aren’t spending their afternoons thinking about the availability of things like kratom, or about 7OH, the kratom compound now sitting squarely in lawmakers’ sights, which is precisely why they think they can get away with using this market as a test case.

Kratom, for those who have never encountered it outside a smoke shop, supplement store, or conversation about alternatives to conventional medicine, is a plant from Southeast Asia that has built a sizeable American following. We’ve written about it previously, here. People buy it in powders, capsules, drinks, and extracts for all sorts of reasons, and whatever one thinks of the product itself (I personally have never tried it), it has existed largely outside the usual pharmacy pipeline.

But 7OH, short for 7-hydroxymitragynine, is now one of the key targets of Georgia’s legislation, and lawmakers are using it as the wedge to drag the wider kratom market into a pharmacist-gated, state-tracked system.

House Bill 968, moving through the legislature in Atlanta, is presented in the oh-so-familiar language of public safety, consumer protection, and responsible oversight. Read past the pieties, and the direction of travel becomes unmistakable. This is an effort to push kratom out of an independent retail market and into a tightly managed, pharmacist-gated, state-tracked system that looks and feels far more like the conventional pharmaceutical model than the marketplace that exists today.

Critics of this approach will recognize the playbook because a version of it surfaced years ago in Nevada and went nowhere. Now the same basic scheme has turned up again in Georgia.

It’s important because it runs counter to what HHS Secretary Robert F. Kennedy Jr has outlined over the last year. He told Joe Rogan, on the subject of peptides, “My hope is that they’re going to get moved to a place where people have access from ethical suppliers.” He was specifically talking about wanting to reverse an FDA decision that prohibited almost 20 peptides from being produced by compounding pharmacies.

At the center of the bill is 7OH. Once Georgia pushes 7OH and related compounds toward Schedule I, the rest of the kratom market can be shoved behind the counter and placed under pharmacist supervision.

“If this can happen to Kratom, which is a botanical that over 24 million Americans are using, nationwide, this can happen to any botanical that they might think is psychoactive or potentially dangerous, even though the science doesn’t support that,” neuroscientist Dr. Michele Ross told The National Pulse.

“Instead of being free and empowered as a consumer to take your health into your own hands, now the state is deciding, hey, ‘we need to track how much you’re using, when you use it, put hours on when it’s available. And you think about a traditional vitamin, or a supplement, right? People take ashwaganda, for example, to relieve stress. That’s psychoactive. Is that going to be put behind the counter, pharmacy style?”

There may be no formal prescription requirement written on the tin, but once a licensed pharmacist has to be present or available for the sale, the practical effect is obvious enough. Out-of-hours access will disappear, casual retail access will narrow sharply, and the online market will cease to be a real market, except for operators who can meet the new licensing and oversight requirements.

This is a full-throated transfer of power from consumers and small retailers to regulators, licensed intermediaries, and the sort of larger corporate interests that do very well whenever a market gets squeezed through a narrower gate.

“I think this is a lot less about safety than it is actually about control here,” Dr. Ross concluded.

CONSUMER TRACKING.

The tracking system is perhaps the most revealing part of the whole thing, because it shows how the state wants this market treated.

Georgia would require retailers to enter purchaser information into a real-time electronic logging system, complete with names, addresses, identification details, product information, and timestamps, and law enforcement would have direct access to the data.

Some of you will remember how pseudoephedrine was pushed behind the counter in the name of stopping methamphetamine production. It is the Sudafed framework, dusted off and applied to kratom. That comparison alone should give people pause, because it means lawful consumers are being folded into a surveillance architecture normally associated with products the state views through a quasi-criminal lens. Critics also worry, not unreasonably, that once such a database exists, it will not stay confined to simple record-keeping and could eventually be used to flag or restrict consumers in the broader world of opioid or Suboxone prescribing and monitoring.

Let us be honest about what all of this adds up to. The endgame looks very much like a market for so-called pharmaceutical-grade kratom, narrow, standardized, bottlenecked, and far easier for large corporate players to monetize. That is how alternative products are usually absorbed into the mainstream system. First, they are demonized, then fenced in, then handed over to approved channels, and by the time the process is complete, the independent sellers are gone, the prices are higher, and everyone is expected to pretend this was simply the natural march of progress. Big Pharma does not need to own every square inch of a market at the start to benefit from this sort of restructuring; it only needs the market remade in a form that suits pharmaceutical logic, distribution, and margins.

MARKET ENDING.

Georgia’s bill would allow only American-grown kratom, which sounds neat in a press release until one remembers that very few kratom trees are grown in the United States compared with the broader supply that exists today. That alone would constrict supply. Then comes the pharmacist requirement, which many consumers will regard as a feature of a system they were trying to avoid in the first place.

Plenty of people have no desire to walk into a pharmacy and explain themselves to a white coat for a product they previously bought lawfully and without fuss, and it is far from clear that the major chains will have any appetite to take this business on anyway. CVS and Walgreens are not exactly known for their enthusiasm for niche products. The likely result is not some seamless transition to a mature and efficient market, but reduced availability, higher prices, and a serious blow to the small shops and specialty retailers for whom kratom is not some decorative side shelf but a meaningful share of revenue. Many of those businesses would struggle to survive the squeeze.

Even the enforcement case is shakier than the bill’s architects would like people to believe. Kratom is a plant, not a laboratory blueprint, and the chemical profile of plant products changes over time. Some of the compounds lawmakers are so eager to police can increase as the material ages and oxidizes, which leaves regulators with a problem they cannot simply legislate away. They may want a clean distinction between natural chemistry and intentional enrichment, but the real world is untidy, and trying to impose a rigid enforcement regime on a changing botanical product is a fine way to create confusion, selective enforcement, and plenty of opportunities for the bureaucracy to get things badly wrong.

All of this matters politically because it cuts directly against the broader rhetoric now coming from Robert F. Kennedy Jr. and the populist health-policy wing that claims to oppose a pharma-dominated system. Kennedy’s appeal in this area has rested on a simple observation that too much of American health care is controlled by pharmaceutical interests, regulatory gatekeepers, and the retail pharmacy model that keeps ordinary people dependent on approved channels.

If you believe the country needs fewer bottlenecks, fewer corporate choke points, fewer licensed gatekeepers, and more room for independent suppliers outside the usual pharmaceutical pipeline, then Georgia is heading in exactly the wrong direction. This bill does not loosen the grip of that system. It expands it, taking a product that has existed outside the pharmacy state and pushing it back inside, complete with pharmacist oversight, surveillance-style tracking, and the quiet promise that everything will be safer once the approved people are in charge.

Today, the excuse is 7OH. Tomorrow, it will be whatever botanical or supplement grows too large outside the pharmacy state.

HB 968 is about far more than kratom. What Georgia is really debating here is whether every product that grows too large outside the conventional medical and pharmaceutical structure must eventually be dragged back into it, catalogued, monitored, bottlenecked, and priced accordingly. Call it safety if you like. Call it modernization if that makes the lobbyists happy. The plain English version is simpler. A market that grew outside the usual corporate channels is being lined up for a familiar sort of capture, and anybody who has spent the past few years railing against the pharmacy state should at least have the decency to admit what this is when it arrives wearing legislative robes.